Beyond tissue injury - Damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis

Journal of the American Society of Nephrology

Volumn 25, Issue 7, 2014, Pages 1387-1400

  Anders, Hans Joachim ^a   Schaefer, Liliana ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; CONNECTIVE TISSUE GROWTH FACTOR; CRYOPYRIN; FIBRONECTIN; HYALURONIC ACID; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 22; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; PURINERGIC RECEPTOR; TAMM HORSFALL GLYCOPROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ACUTE KIDNEY TUBULE NECROSIS; ALLOIMMUNITY; AUTOIMMUNITY; BLOOD VESSEL PERMEABILITY; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DISEASE ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE INJURY; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE DISORDER; KIDNEY TUBULE NECROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; TISSUE REGENERATION; ACUTE KIDNEY FAILURE; ANIMAL; ARF; CHRONIC KIDNEY FAILURE; FIBROSIS; GN; IMMUNOLOGY; IMMUNOLOGY AND PATHOLOGY; INFLAMMATION; INJURY; KIDNEY; PATHOLOGY; PHYSIOLOGY; REGENERATION;

ARF; GN; IMMUNOLOGY AND PATHOLOGY;

ACUTE KIDNEY INJURY; ANIMALS; FIBROSIS; HUMANS; INFLAMMASOMES; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY; KIDNEY DISEASES; REGENERATION; RENAL INSUFFICIENCY, CHRONIC; TOLL-LIKE RECEPTORS;

EID: 84907195162     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014010117     Document Type: Review

References (201)

1. Wallach D, Kang TB, Kovalenko A: Concepts of tissue injury and cell death in inflammation: A historical perspective. Nat Rev Immunol 14: 51-59, 2014
2. Medzhitov R: Origin and physiological roles of inflammation. Nature 454: 428-435, 2008
3. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045, 1994
4. Kurts C, Panzer U, Anders HJ, Rees AJ: The immune system and kidney disease: Basic concepts and clinical implications. Nat Rev Immunol 13: 738-753, 2013
5. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, Akira S, van der Poll T, Weening JJ, Florquin S: Renal-associated TLR2 mediates ischemia/ reperfusion injury in the kidney. J Clin Invest 115: 2894-2903, 2005
6. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ: TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 117: 2847-2859, 2007
7. Rock KL, Latz E, Ontiveros F, Kono H: The sterile inflammatory response. Annu Rev Immunol 28: 321-342, 2010
8. Anders HJ: Toll-like receptors and danger signaling in kidney injury. J AmSoc Nephrol 21: 1270-1274, 2010
9. Anders HJ, Banas B, Schlöndorff D: Signaling danger: Toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15: 854-867, 2004
10. Anders HJ, Muruve DA: The inflammasomes in kidney disease. J Am Soc Nephrol 22: 1007-1018, 2011
11. Rosin DL, Okusa MD: Dangers within: DAMP responses to damage and cell death in kidney disease. J Am Soc Nephrol 22: 416-425, 2011
12. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE: Cell death. NEngl J Med 361: 1570-1583, 2009
13. Ravichandran KS: Beginnings of a good apoptotic meal: The find-me and eat-me signaling pathways. Immunity 35: 445-455, 2011
14. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/ paracrine mechanisms involving TGFbeta, PGE2, and PAF. J Clin Invest 101: 890-898, 1998
15. Freire-de-Lima CG, Nascimento DO, Soares MB, Bozza PT, Castro-Faria-Neto HC, de Mello FG, DosReis GA, Lopes MF: Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 403: 199-203, 2000
16. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R: In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note. Hepatology 21: 1465-1468, 1995
17. Vanden Berghe T, Linkermann A, Jouan- Lanhouet S, Walczak H, Vandenabeele P: Regulated necrosis: The expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 15: 135-147, 2014
18. Linkermann A, Green D: Mechanisms of disease: Necroptosis. N Engl J Med 370: 455-465, 2014
19. Lau A, Wang S, Jiang J, Haig A, Pavlosky A, Linkermann A, Zhang ZX, Jevnikar AM: RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am J Transplant 13: 2805-2818, 2013
20. Linkermann A, Bräsen JH, Darding M, Jin MK, Sanz AB, Heller JO, De Zen F, Weinlich R, Ortiz A, Walczak H, Weinberg JM, Green DR, Kunzendorf U, Krautwald S: Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci U S A 110: 12024-12029, 2013
21. Linkermann A, Bräsen JH, HimmerkusN, Liu S, Huber TB, Kunzendorf U, Krautwald S: Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int 81: 751-761, 2012
22. Linkermann A, Heller JO, Prókai A, Weinberg JM, De Zen F, Himmerkus N, Szabó AJ, Bräsen JH, Kunzendorf U, Krautwald S: The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol 24: 1545-1557, 2013
23. Tristão VR, Gonçalves PF, Dalboni MA, Batista MC, Durão MS Jr, Monte JC: Nec-1 protects against nonapoptotic cell death in cisplatin-induced kidney injury. Ren Fail 34: 373-377, 2012
24. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR: Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149: 1060-1072, 2012
25. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A: Neutrophil extracellular traps kill bacteria. Science 303: 1532-1535, 2004
26. Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z, Gröne HJ, Brinkmann V, Jenne DE: Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 15: 623-625, 2009
27. Case CL, Kohler LJ, Lima JB, Strowig T, de Zoete MR, Flavell RA, Zamboni DS, Roy CR: Caspase-11 stimulates rapid flagellinindependent pyroptosis in response to Legionella pneumophila. Proc Natl Acad Sci U S A 110: 1851-1856, 2013
28. Fink SL, Cookson BT: Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol 8: 1812-1825, 2006
29. Krautwald S, Linkermann A: The fire within: Pyroptosis in the kidney. AmJ Physiol Renal Physiol 306: F168-F169, 2014
30. Yang JR, Yao FH, Zhang JG, Ji ZY, Li KL, Zhan J, Tong YN, Lin LR, He YN: Ischemiareperfusion induces renal tubule pyroptosis via the CHOP-caspase-11 pathway. Am J Physiol Renal Physiol 306: F75-F84, 2014
31. Wight TN, Potter-Perigo S: The extracellular matrix: An active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol 301: G950-G955, 2011
32. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, Noble PW: Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11: 1173-1179, 2005
33. Jiang D, Liang J, Noble PW: Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23: 435-461, 2007
34. Noble PW: Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 21: 25-29, 2002
35. Noble PW, Jiang D: Matrix regulation of lung injury, inflammation, and repair: The role of innate immunity. Proc Am Thorac Soc 3: 401-404, 2006
36. Schaefer L: Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol 22: 1200-1207, 2011
37. Frey H, Schroeder N, Manon-Jensen T, Iozzo RV, Schaefer L: Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J 280: 2165-2179, 2013
38. Moreth K, Brodbeck R, Babelova A, GretzN, Spieker T, Zeng-Brouwers J, Pfeilschifter J, Young MF, Schaefer RM, Schaefer L: The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest 120: 4251-4272, 2010
39. Moreth K, Iozzo RV, Schaefer L: Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 11: 2084-2091, 2012
40. Nastase MV, Young MF, Schaefer L: Biglycan: A multivalent proteoglycan providing structure and signals. J Histochem Cytochem 60: 963-975, 2012
41. Schaefer L: Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol 10: 185-190, 2010
42. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Götte M, Malle E, Schaefer RM, Gröne HJ: The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223-2233, 2005
43. Schaefer L, Iozzo RV: Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev 22: 56-57, 2012
44. Schaefer L, Schaefer RM: Proteoglycans: From structural compounds to signaling molecules. Cell Tissue Res 339: 237-246, 2010
45. Sorokin L: The impact of the extracellular matrix on inflammation. Nat Rev Immunol 10: 712-723, 2010
46. Schaefer L, Gröne HJ, Raslik I, Robenek H, Ugorcakova J, Budny S, Schaefer RM, Kresse H: Small proteoglycans of normal adult human kidney: Distinct expression patterns of decorin, biglycan, fibromodulin, and lumican. Kidney Int 58: 1557-1568, 2000
47. Schaefer L, Raslik I, Grone HJ, Schonherr E, Macakova K, Ugorcakova J, Budny S, Schaefer RM, Kresse H: Small proteoglycans in human diabetic nephropathy:Discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB J 15: 559-561, 2001
48. Schaefer L, Mihalik D, BabelovaA, Krzyzankova M, GröneHJ, Iozzo RV, Young MF, Seidler DG, Lin G, Reinhardt DP, Schaefer RM: Regulation of fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury. Am J Pathol 165: 383-396, 2004
49. Schaefer L, Macakova K, Raslik I, Micegova M, Gröne HJ, Schönherr E, Robenek H, Echtermeyer FG, Grässel S, Bruckner P, Schaefer RM, Iozzo RV, Kresse H: Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 160: 1181-1191, 2002
50. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Gröne HJ, Reinhardt DP, Pfeilschifter J, Iozzo RV, Schaefer RM: Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin- like growth factor-I receptor and mammalian target of rapamycin. Am J Pathol 170: 301-315, 2007
51. Merline R, Lazaroski S, Babelova A, Tsalastra-Greul W, Pfeilschifter J, Schluter KD, Gunther A, Iozzo RV, Schaefer RM, Schaefer L: Decorin deficiency in diabetic mice: Aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol 60[Suppl 4]: 5-13, 2009
52. Merline R, Schaefer RM, Schaefer L: The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal 3: 323-335, 2009
53. Johnsson C, Tufveson G, Wahlberg J, Hällgren R: Experimentally-induced warm renal ischemia induces cortical accumulation of hyaluronan in the kidney. Kidney Int 50: 1224-1229, 1996
54. Wüthrich RP: The proinflammatory role of hyaluronan-CD44 interactions in renal injury. Nephrol Dial Transplant 14: 2554-2556, 1999
55. Wells A, Larsson E, Hanás E, Laurent T, Hällgren R, Tufveson G: Increased hyaluronan in acutely rejecting human kidney grafts. Transplantation 55: 1346-1349, 1993
56. Sibalic V, Fan X, Loffing J, Wüthrich RP: Upregulated renal tubular CD44, hyaluronan, and osteopontin in kdkd mice with interstitial nephritis.Nephrol Dial Transplant 12: 1344-1353, 1997
57. Feusi E, Sun L, Sibalic A, Beck-Schimmer B, Oertli B, Wüthrich RP: Enhanced hyaluronan synthesis in the MRL-Fas(lpr) kidney: Role of cytokines. Nephron 83: 66-73, 1999
58. MeirovitzA, Goldberg R, BinderA, Rubinstein AM, Hermano E, Elkin M: Heparanase in inflammation and inflammation-associated cancer. FEBS J 280: 2307-2319, 2013
59. Vlodavsky I, Iozzo RV, Sanderson RD: Heparanase: Multiple functions in inflammation, diabetes and atherosclerosis. Matrix Biol 32: 220-222, 2013
60. Goldberg R, Meirovitz A, Hirshoren N, Bulvik R, Binder A, Rubinstein AM, Elkin M: Versatile role of heparanase in inflammation. Matrix Biol 32: 234-240, 2013
61. Parish CR, Freeman C, Ziolkowski AF, He YQ, Sutcliffe EL, Zafar A, Rao S, Simeonovic CJ: Unexpected new roles for heparanase in type 1 diabetes and immune gene regulation. Matrix Biol 32: 228-233, 2013
62. Shafat I, Agbaria A, Boaz M, Schwartz D, Baruch R, Nakash R, Ilan N, Vlodavsky I, Weinstein T: Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS ONE 7: e44076, 2012
63. Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000
64. Monaco S, Sparano V, GioiaM, Sbardella D, Di Pierro D, Marini S, Coletta M: Enzymatic processing of collagen IV by MMP-2 (gelatinase A) affects neutrophil migration and it is modulated by extracatalytic domains. Protein Sci 15: 2805-2815, 2006
65. Riggins KS, Mernaugh G, Su Y, Quaranta V, Koshikawa N, Seiki M, Pozzi A, Zent R:MT1- MMP-mediated basement membrane remodeling modulates renal development. Exp Cell Res 316: 2993-3005, 2010
66. Boor P, Ostendorf T, Floege J: Renal fibrosis: Novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 6: 643-656, 2010
67. Nony PA, Schnellmann RG: Interactions between collagen IV and collagen-binding integrins in renal cell repair after sublethal injury. Mol Pharmacol 60: 1226-1234, 2001
68. Scott IC, Imamura Y, Pappano WN, Troedel JM, Recklies AD, Roughley PJ, Greenspan DS: Bone morphogenetic protein-1 processes probiglycan.JBiolChem275: 30504-30511, 2000
69. Calabrese GC, Gazzaniga S, Oberkersch R, Wainstok R:Decorin andbiglycan expression: Its relation with endothelial heterogeneity. Histol Histopathol 26: 481-490, 2011
70. BoivinWA, ShacklefordM, Vanden Hoek A, Zhao H, Hackett TL, Knight DA, Granville DJ: Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-b1. PLoS ONE 7: e33163, 2012
71. Monfort J, Tardif G, Reboul P, Mineau F, Roughley P, Pelletier JP, Martel-Pelletier J: Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease- 13: identification of a new biglycan cleavage site. Arthritis Res Ther 8: R26, 2006
72. Genovese F, Barascuk N, Larsen L, Larsen MR, Nawrocki A, Li Y, Zheng Q, Wang J, Veidal SS, Leeming DJ, Karsdal MA: Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases. Fibrogenesis Tissue Repair 6: 9, 2013
73. Nastase MV, Iozzo RV, Schaefer L: Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology [published online ahead of print February 5, 2014]. BiochimBiophys Acta doi:10.1016/j.bbagen.2014.01.035
74. Moreth K, Frey H, Hubo M, Zeng-Brouwers J, Nastase MV, Hsieh LT, Haceni R, Pfeilschifter J, Iozzo RV, Schaefer L: Biglycan- triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury [published online ahead of print January 28, 2014].Matrix Biol doi:10.1016/j.matbio.2014.01.010
75. Zeng-Brouwers J, Beckmann J, NastaseMV, Iozzo RV, Schaefer L: De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/ TRIF pathways [published online ahead of print December 18, 2013]. Matrix Biol doi:10.1016/j.matbio.2013.12.003
76. Jyo Y, Sasaki T, Nomura S, Tamai H, Kawai S, Osawa G, Nakao N, Kusakabe M: Expression of tenascin in mesangial injury in experimental glomerulonephritis. Exp Nephrol 5: 423-428, 1997
77. Vial C, Gutiérrez J, Santander C, Cabrera D, Brandan E: Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity. J Biol Chem 286: 24242-24252, 2011
78. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhão JG, Lemarchand P, Pfeilschifter J, Schaefer RM, Iozzo RV, Schaefer L: Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 4: ra75, 2011
79. El-Achkar TM, Wu XR: Uromodulin in kidney injury: An instigator, bystander, or protector? Am J Kidney Dis 59: 452-461, 2012
80. SäemannMD, Weichhart T, ZeydaM, Staffler G, Schunn M, Stuhlmeier KM, Sobanov Y, Stulnig TM, Akira S, von Gabain A, von Ahsen U, Hörl WH, Zlabinger GJ: Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest 115: 468-475, 2005
81. Darisipudi MN, Thomasova D, Mulay SR, Brech D, Noessner E, Liapis H, Anders HJ: Uromodulin triggers IL-1b-dependent innate immunity via the NLRP3 inflammasome. J Am Soc Nephrol 23: 1783-1789, 2012
82. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241, 2006
83. Mulay SR, Evan A, Anders HJ: Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 29: 507-514, 2014
84. Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, Muruve D, Shi Y, Munro F, Liapis H, Anders HJ: Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1b secretion. J Clin Invest 123: 236-246, 2013
85. Leventhal JS, Schröppel B: Toll-like receptors in transplantation: Sensing and reacting to injury. Kidney Int 81: 826-832, 2012
86. Marshak-Rothstein A, Rifkin IR: Immunologically active autoantigens: The role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 25: 419-441, 2007
87. Allam R, Anders HJ: The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 20: 538-544, 2008
88. Anders HJ, Schlöndorff D: Toll-like receptors: Emerging concepts in kidney disease. Curr Opin Nephrol Hypertens 16: 177-183, 2007
89. Allam R, Scherbaum CR, Darisipudi MN, Mulay SR, Hägele H, Lichtnekert J, Hagemann JH, Rupanagudi KV, RyuM, Schwarzenberger C, Hohenstein B, Hugo C, Uhl B, Reichel CA, Krombach F, MonestierM, LiapisH, MorethK, Schaefer L, Anders HJ: Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol 23: 1375-1388, 2012
90. Banas MC, Banas B, Hudkins KL, Wietecha TA, Iyoda M, Bock E, Hauser P, Pippin JW, Shankland SJ, Smith KD, Stoelcker B, Liu G, Gröne HJ, Krämer BK, Alpers CE: TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 19: 704-713, 2008
91. Gurkan S, Cabinian A, Lopez V, Bhaumik M, Chang JM, Rabson AB, Mundel P: Inhibition of type I interferon signalling prevents TLR ligand-mediated proteinuria. J Pathol 231: 248-256, 2013
92. Khandoga AG, Khandoga A, Anders HJ, Krombach F: Postischemic vascular permeability requires both TLR-2 and TLR-4, but only TLR-2 mediates the transendothelial migration of leukocytes. Shock 31: 592-598, 2009
93. Pawar RD, Castrezana-Lopez L, Allam R, KulkarniOP, Segerer S, Radomska E, Meyer TN, Schwesinger CM, Akis N, Gröne HJ, Anders HJ: Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. Immunology 128[Suppl]: e206-e221, 2009
94. Allam R, Darisipudi MN, Tschopp J, Anders HJ: Histones trigger sterile inflammation by activating the NLRP3 inflammasome. Eur J Immunol 43: 3336-3342, 2013
95. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, Bruckner P, Pfeilschifter J, Schaefer RM, Gröne HJ, Schaefer L: Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem284: 24035-24048, 2009
96. Schroder K, Tschopp J: The inflammasomes. Cell 140: 821-832, 2010
97. Knauf F, Asplin JR, Granja I, Schmidt IM, Moeckel GW, David RJ, Flavell RA, Aronson PS: NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 84: 895- 901, 2013
98. Lorenz G, Darisipudi MN, Anders HJ: Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 29: 41- 48, 2014
99. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT: Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol 187: 2626-2631, 2011
100. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT: Extracellular histones are major mediators of death in sepsis. Nat Med 15: 1318-1321, 2009
101. Fenton KA, Tømmerås B, Marion TN, Rekvig OP: Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity 43: 179-188, 2010
102. Mjelle JE, Rekvig OP, Van Der Vlag J, Fenton KA: Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity 44: 373-383, 2011
103. Mortensen ES, Rekvig OP: Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 20: 696-704, 2009
104. Bosch X: Systemic lupus erythematosus and the neutrophil.NEngl J Med365: 758-760, 2011
105. Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A: Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 107: 9813-9818, 2010
106. Romagnani P, Anders HJ: What can tubular progenitor cultures teach us about kidney regeneration? Kidney Int 83: 351-353, 2013
107. Angelotti ML, Ronconi E, Ballerini L, Peired A, Mazzinghi B, Sagrinati C, Parente E, Gacci M, Carini M, Rotondi M, Fogo AB, Lazzeri E, Lasagni L, Romagnani P: Characterization of renal progenitors committed toward tubular lineage and their regenerative potential in renal tubular injury. Stem Cells 30: 1714-1725, 2012
108. Gupta S, Verfaillie C, Chmielewski D, Kren S, Eidman K, Connaire J, Heremans Y, Lund T, Blackstad M, Jiang Y, Luttun A, Rosenberg ME: Isolation and characterization of kidney- derived stem cells. J Am Soc Nephrol 17: 3028-3040, 2006
109. Kitamura S, Yamasaki Y, Kinomura M, Sugaya T, Sugiyama H, Maeshima Y, Makino H: Establishment and characterization of renal progenitor like cells from S3 segment of nephron in rat adult kidney. FASEB J 19: 1789-1797, 2005
110. Langworthy M, Zhou B, de Caestecker M, Moeckel G, Baldwin HS: NFATc1 identifies a population of proximal tubule cell progenitors. J Am Soc Nephrol 20: 311-321, 2009
111. Lindgren D, BoströmAK, Nilsson K, Hansson J, Sjölund J, Möller C, Jirström K, Nilsson E, Landberg G, Axelson H, Johansson ME: Isolation and characterization of progenitor-like cells fromhuman renal proximal tubules. Am J Pathol 178: 828-837, 2011
112. Maeshima A, Yamashita S, Nojima Y: Identification of renal progenitor-like tubular cells that participate in the regeneration processes of the kidney. J Am SocNephrol 14: 3138-3146, 2003
113. Sallustio F, Costantino V, Cox SN, Loverre A, Divella C, Rizzi M, Schena FP: Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvesicle-shuttled decorin. Kidney Int 83: 392-403, 2013
114. Sallustio F, De Benedictis L, Castellano G, Zaza G, LoverreA, Costantino V, Grandaliano G, Schena FP: TLR2 plays a role in the activation of human resident renal stem/progenitor cells. FASEB J 24: 514-525, 2010
115. KulkarniOP, Hartter I, Mulay SR, Hagemann J, Darisipudi MN, Kumar VR S, Romoli S, Thomasova D, RyuM, Kobold S, Anders HJ: Toll-like receptor 4-induced IL-22 accelerates kidney regeneration [published online ahead of print January 23, 2014]. J Am Soc Nephrol doi:10.1681/ASN.2013050528
116. Anders HJ: Four danger response programs determine glomerular and tubulointerstitial kidney pathology: Clotting, inflammation, epithelial and mesenchymal healing. Organogenesis 8: 29-40, 2012
117. Liu Y: Cellular and molecularmechanisms of renal fibrosis. Nat Rev Nephrol 7: 684-696, 2011
118. Lee SB, Kalluri R: Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl 119: S22-S26, 2010
119. Liu Y: Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006
120. Chung AC, Lan HY: Chemokines in renal injury.JAmSocNephrol 22: 802-809, 2011
121. McKee CM, Penno MB, Cowman M, BurdickMD, Strieter RM, Bao C, Noble PW: Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 98: 2403-2413, 1996
122. Hodge-Dufour J, Noble PW, Horton MR, Bao C, WysokaM, BurdickMD, Strieter RM, Trinchieri G, Puré E: Induction of IL-12 and chemokinesby hyaluronan requires adhesiondependent priming of resident but not elicited macrophages. J Immunol 159: 2492-2500, 1997
123. Black KE, Collins SL, Hagan RS, Hamblin MJ, Chan-Li Y, Hallowell RW, Powell JD, Horton MR: Hyaluronan fragments induce IFNb via a novel TLR4-TRIF-TBK1-IRF3- dependent pathway. J Inflamm (Lond) 10: 23, 2013
124. Ebid R, Lichtnekert J, Anders HJ: Hyaluronan is not a ligand but a regulator of Toll-like receptor signaling in mesangial cells. Role of extracellular matrix in innate immunity [published online ahead of print January 21, 2014]. ISRN Nephrol doi:10.1155/2014/714081
125. Brennan TV, Lin L, Huang X, CardonaDM, Li Z, Dredge K, Chao NJ, Yang Y: Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood 120: 2899-2908, 2012
126. Wrenshall LE, Stevens RB, Cerra FB, Platt JL: Modulation of macrophage and B cell function by glycosaminoglycans. J Leukoc Biol 66: 391-400, 1999
127. Bani-Hani AH, Leslie JA, Asanuma H, Dinarello CA, Campbell MT, Meldrum DR, Zhang H, Hile K, Meldrum KK: IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. Kidney Int 76: 500-511, 2009
128. Jones LK, O'Sullivan KM, Semple T, Kuligowski MP, Fukami K, Ma FY, Nikolic- Paterson DJ, Holdsworth SR, Kitching AR: IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis. Nephrol Dial Transplant 24: 3024-3032, 2009
129. Vesey DA, Cheung C, Cuttle L, Endre Z, Gobe G, Johnson DW: Interleukin-1beta stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factorbeta- dependent mechanism. J Lab Clin Med 140: 342-350, 2002
130. Vesey DA, Cheung CW, Cuttle L, Endre ZA, Gobé G, Johnson DW: Interleukin-1beta induces human proximal tubule cell injury, alpha-smooth muscle actin expression and fibronectin production. Kidney Int 62: 31-40, 2002
131. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, Hemmelgarn BR, Beck PL, Muruve DA: The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 21: 1732- 1744, 2010
132. Pulskens WP, Butter LM, Teske GJ, Claessen N, Dessing MC, Flavell RA, Sutterwala FS, Florquin S, Leemans JC:Nlrp3 prevents early renal interstitial edema and vascular permeability in unilateral ureteral obstruction. PLoS ONE 9: e85775, 2014
133. Anders HJ, Lech M: NOD-like and Toll-like receptors or inflammasomes contribute to kidney disease in a canonical and a noncanonical manner. Kidney Int 84: 225-228, 2013
134. Wang W, Wang X, Chun J, Vilaysane A, Clark S, French G, Bracey NA, Trpkov K, Bonni S, Duff HJ, Beck PL, Muruve DA: Inflammasome-independent NLRP3 augments TGF-b signaling in kidney epithelium. J Immunol 190: 1239-1249, 2013
135. Scarpellini A, Huang L, Burhan I, Schroeder N, Funck M, Johnson TS, Verderio EA: Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis [published online ahead of print December 19, 2013]. J Am Soc Nephrol doi:10.1681/ASN.2013050563
136. To WS, Midwood KS: Plasma and cellular fibronectin: Distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair 4: 21, 2011
137. Yamaguchi Y, Mann DM, Ruoslahti E: Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346: 281-284, 1990
138. Droguett R, Cabello-Verrugio C, Riquelme C, Brandan E: Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol 25: 332-341, 2006
139. Glowacki F, Savary G, Gnemmi V, Buob D, Van der Hauwaert C, Lo-Guidice JM, Bouyé S, Hazzan M, Pottier N, Perrais M, Aubert S, Cauffiez C: Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS ONE 8: e58014, 2013
140. Eleftheriadis T, Pissas G, Liakopoulos V, Stefanidis I, Lawson BR: Toll-like receptors and their role in renal pathologies. Inflamm Allergy Drug Targets 11: 464-477, 2012
141. Leemans JC, et al: Toll-like receptors, NOD-like receptors and the inflammasome in kidney disease. Nat Rev Nephrol in minor revision, 2014
142. Leelahavanichkul A, Huang Y, Hu X, Zhou H, Tsuji T, Chen R, Kopp JB, Schnermann J, Yuen PS, Star RA: Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1. Kidney Int 80: 1198- 1211, 2011
143. Rabadi MM, Ghaly T, Goligorksy MS, Ratliff BB: HMGB1 in renal ischemic injury. Am J Physiol Renal Physiol 303: F873-F885, 2012
144. Wang H, Bloom O, Zhang M, Vishnubhakat JM, OmbrellinoM, Che J, Frazier A, YangH, Ivanova S, Borovikova L, ManogueKR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999
145. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR, Chadban SJ: HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 21: 1878-1890, 2010
146. Arumugam TV, Okun E, Tang SC, Thundyil J, Taylor SM, Woodruff TM: Toll-like receptors in ischemia-reperfusion injury. Shock 32: 4-16, 2009
147. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson- Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE: High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 254: 375-385, 2003
148. WuH, Steenstra R, de Boer EC, ZhaoCY, Ma J, van der Stelt JM, Chadban SJ: Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice. Kidney Int 85: 824-832, 2014
149. Günthner R, Kumar VR, Lorenz G, Anders HJ, Lech M: Pattern-recognition receptor signaling regulator mRNA expression in humans and mice, and in transient inflammation or progressive fibrosis. Int J Mol Sci 14: 18124-18147, 2013
150. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, Eisenbarth SC, Florquin S, Flavell RA, Leemans JC, Sutterwala FS:Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 106: 20388-20393, 2009
151. Shigeoka AA, Holscher TD, King AJ, Hall FW, Kiosses WB, Tobias PS, Mackman N, McKay DB: TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88- dependent and -independent pathways. J Immunol 178: 6252-6258, 2007
152. Shigeoka AA, Mueller JL, Kambo A, Mathison JC, King AJ, Hall WF, Correia JS, Ulevitch RJ, Hoffman HM, McKay DB: An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol 185: 6277-6285, 2010
153. Lichtnekert J, Vielhauer V, Zecher D, Kulkarni OP, Clauss S, Segerer S, Hornung V, Mayadas TN, Beutler B, Akira S, Anders HJ: Trif is not required for immune complex glomerulonephritis: Dying cells activate mesangial cells via Tlr2/Myd88 rather than Tlr3/Trif. Am J Physiol Renal Physiol 296: F867-F874, 2009
154. Zickert A, Palmblad K, Sundelin B, Chavan S, Tracey KJ, Bruchfeld A, Gunnarsson I: Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 14: R36, 2012
155. Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K, Gunnarsson I:High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 17: 29-35, 2011
156. Patole PS, Zecher D, Pawar RD, Gröne HJ, Schlöndorff D, Anders HJ: G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 16: 3273-3280, 2005
157. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ: Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 18: 1721-1731, 2007
158. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ: Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417-428, 2006
159. Lech M, Anders HJ: The pathogenesis of lupus nephritis. J Am Soc Nephrol 24: 1357-1366, 2013
160. Chen K, Zhang J, ZhangW, Zhang J, Yang J, Li K, He Y: ATP-P2X4 signaling mediates NLRP3 inflammasome activation: A novel pathway of diabetic nephropathy. Int J Biochem Cell Biol 45: 932-943, 2013
161. Lin M, Yiu WH, Li RX, Wu HJ, Wong DW, Chan LY, Leung JC, Lai KN, Tang SC: The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int 83: 887-900, 2013
162. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J: Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11: 136-140, 2010
163. Stridh S, Palm F, Hansell P: Renal interstitial hyaluronan: Functional aspects during normal and pathological conditions. Am J Physiol Regul Integr Comp Physiol 302: R1235-R1249, 2012
164. Mudaliar H, Pollock C, Komala MG, Chadban S, Wu H, Panchapakesan U: The role of Toll-like receptor proteins (TLR) 2 and 4 inmediating inflammation in proximal tubules. Am J Physiol Renal Physiol 305: F143-F154, 2013
165. Thompson J, Wilson P, Brandewie K, Taneja D, Schaefer L, Mitchell B, Tannock LR: Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol 179: 1179-1187, 2011
166. Campo GM, Avenoso A, Micali A, Nastasi G, Squadrito F, Altavilla D, Bitto A, Polito F, Rinaldi MG, Calatroni A, D'Ascola A, Campo S: High-molecular weight hyaluronan reduced renal PKC activation in genetically diabetic mice. Biochim Biophys Acta 1802: 1118-1130, 2010
167. Migliorini A, Anders HJ: A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 8: 183-189, 2012
168. Migliorini A, Angelotti ML, Mulay SR, Kulkarni OO, Demleitner J, Dietrich A, Sagrinati C, Ballerini L, Peired A, Shankland SJ, Liapis H, Romagnani P, Anders HJ: The antiviral cytokines IFN-a and IFN-b modulate parietal epithelial cells and promote podocyte loss: Implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am J Pathol 183: 431-440, 2013
169. Pawar RD, Patole PS, Ellwart A, Lech M, Segerer S, Schlondorff D, Anders HJ: Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol 17: 3365-3373, 2006
170. Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schlöndorff D, Anders HJ: Tolllike receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 17: 141-149, 2006
171. Correa-Costa M, Braga TT, Semedo P, Hayashida CY, Bechara LR, Elias RM, Barreto CR, Silva-Cunha C, Hyane MI, Gonçalves GM, Brum PC, Fujihara C, Zatz R, Pacheco- Silva A, Zamboni DS, Camara NO: Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis. PLoS ONE 6: e29004, 2011
172. Allam R, Lichtnekert J, Moll AG, Taubitz A, Vielhauer V, Anders HJ: Viral RNA and DNA trigger common antiviral responses in mesangial cells. J Am Soc Nephrol 20: 1986-1996, 2009
173. Anders HJ, Banas B, Linde Y, Weller L, Cohen CD, Kretzler M, Martin S, Vielhauer V, SchlöndorffD, GröneHJ:BacterialCpG-DNA aggravates immune complex glomerulonephritis: Role of TLR9-mediated expression of chemokines and chemokine receptors. J Am Soc Nephrol 14: 317-326, 2003
174. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de LemaG, Strutz F, Bauer S, Rutz M, Wagner H, GröneHJ, Schlöndorff D: Activation of Toll-like receptor-9 induces progression of renal disease inMRL-Fas(lpr) mice. FASEB J 18: 534-536, 2004
175. Merino A, Nogueras S, García-Maceira T, Rodríguez M, Martin-Malo A, Ramirez R, Carracedo J, Aljama P: Bacterial DNA and endothelialdamagein haemodialysis patients. Nephrol Dial Transplant 23: 3635-3642, 2008
176. Patole PS, Gröne HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlöndorff D, Anders HJ: Viral doublestranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 16: 1326-1338, 2005
177. Patole PS, Pawar RD, Lichtnekert J, Lech M, Kulkarni OP, Ramanjaneyulu A, Segerer S, Anders HJ: Coactivation of Toll-like receptor- 3 and -7 in immune complex glomerulonephritis. J Autoimmun 29: 52-59, 2007
178. ZhangQ, RaoofM, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ: Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104-107, 2010
179. GonçalvesRG, Gabrich L, RosárioAJr, Takiya CM, Ferreira ML, Chiarini LB, Persechini PM, Coutinho-Silva R, Leite M Jr: The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 70: 1599-1606, 2006
180. Ji X, Naito Y, Weng H, Endo K, Ma X, Iwai N: P2X7 deficiency attenuates hypertension and renal injury in deoxycorticosterone acetate-salt hypertension. Am J Physiol Renal Physiol 303: F1207-F1215, 2012
181. Solini A, Menini S, Rossi C, Ricci C, Santini E, Blasetti Fantauzzi C, Iacobini C, Pugliese G: The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: Possible role of NLRP3 inflammasome activation. J Pathol 231: 342- 353, 2013
182. Wang C, Pan Y, ZhangQY, Wang FM, Kong LD: Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoSONE 7: e38285, 2012
183. Penfold SA, Coughlan MT, Patel SK, Srivastava PM, Sourris KC, Steer D, Webster DE, Thomas MC, MacIsaac RJ, Jerums G, Burrell LM, Cooper ME, Forbes JM: Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 78: 287-295, 2010
184. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Häcker H, Wagner H: Endocytosed HSP60s use tolllike receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 276: 31332-31339, 2001
185. Kuroda M, Sasamura H, Kobayashi E, Shimizu-Hirota R, Nakazato Y, Hayashi M, Saruta T:Glomerular expression of biglycan and decorin and urinary levels of decorin in primary glomerular disease. Clin Nephrol 61: 7-16, 2004
186. Schaefer L, Hausser H, Altenburger M, Ugorcakova J, August C, Fisher LW, Schaefer RM, Kresse H: Decorin, biglycan and their endocytosis receptor in rat renal cortex. Kidney Int 54: 1529-1541, 1998
187. Motojima M, Matsusaka T, Kon V, Ichikawa I: Fibrinogen that appears in Bowman's space of proteinuric kidneys in vivo activates podocyte Toll-like receptors 2 and 4 in vitro. Nephron, Exp Nephrol 114: e39-e47, 2010
188. Sörensen I, Susnik N, Inhester T, Degen JL, Melk A, Haller H, Schmitt R: Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int 80: 1035-1044, 2011
189. Okamura Y, WatariM, Jerud ES, YoungDW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd: The extra domain A of fibronectin activates Toll-like receptor 4. J BiolChem276: 10229-10233, 2001
190. Jiang D, Liang J, Noble PW: Hyaluronan as an immune regulator in human diseases. Physiol Rev 91: 221-264, 2011
191. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC: Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 195: 99-111, 2002
192. Yung S, Chan TM: The role of hyaluronan and CD44 in the pathogenesis of lupus nephritis. Autoimmune Dis 2012: 207190, 2012
193. Johnson GB, Brunn GJ, Kodaira Y, Platt JL: Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 168: 5233-5239, 2002
194. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, van Kuppevelt T, Meirovitz A, Pisano C, Li JP, van der Vlag J, Vlodavsky I, Elkin M: Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61: 208-216, 2012
195. Kim S, Takahashi H, LinWW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106, 2009
196. Rudnicki M, Perco P, Neuwirt H, Noppert SJ, Leierer J, Sunzenauer J, Eder S, Zoja C, Eller K, Rosenkranz AR, MüllerGA, Mayer B, Mayer G: Increased renal versican expression is associated with progression of chronic kidney disease. PLoS ONE 7: e44891, 2012
197. Halle A, Hornung V, Petzold GC, Stewart CR, MonksBG, Reinheckel T, FitzgeraldKA, Latz E, Moore KJ, Golenbock DT: The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9: 857-865, 2008
198. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, KränkelN, KaniaG, Zewinger S, Akhmedov A, Shi Y, Martin T, Perisa D, Winnik S, Müller MF, Sester U, Wernicke G, Jung A, Gutteck U, Eriksson U, Geisel J, Deanfield J, von Eckardstein A, Lüscher TF, Fliser D, Bahlmann FH, Landmesser U: Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38: 754-768, 2013
199. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K, Suarna C, Eller P, Tölle M, Gerner C, Zlabinger GJ, van der Giet M, Hörl WH, Stocker R, Säemann MD: Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 23: 934-947, 2012
200. De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, Vogelhuber J, Kraut M, Ulas T, Kerksiek A, Krebs W, Bode N, Grebe A, Fitzgerald ML, Hernandez NJ, Williams BR, Knolle P, Kneilling M, Röcken M, Lütjohann D, Wright SD, Schultze JL, Latz E: High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 15: 152-160, 2014
201. El-Achkar TM, Wu XR, Rauchman M, McCracken R, Kiefer S, Dagher PC: Tamm- Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Renal Physiol 295: F534-F544, 2008